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ABI  Anaerobic bloodstream infection
ANC  Absolute neutrophil count
APSCT  Autologous peripheral stem cell transplantation
BEAM  BCNU, etoposide, cytosine arabinoside, melphalan
BMI  Body mass index
CHX  Chlorhexidine digluconate
CI  Confidence interval
CMR  Complete morphological remission
CR  Complete remission
DG  Diagnosis
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E2  17-beta-estradiol
GI  Gastrointestinal tract
G-CSF  Granulocyte-colony stimulating factor
G/L  Giga per Litre
GVHD  Graft-versus-host disease
HL  Hodgkin lymphoma
HSCT  Haematopoietic stem cell transplantation
HRT  Hormone replacement therapy
IgA  Immunoglobulin A
IgG  Immunoglobulin G
IMWG  International Myeloma Working Group
LDH  Lactate-dehydrogenase
MTX  Methotrexate
MBI  Mucosal barrier injury
MM  Multiple myeloma
NHL  Non-Hodgkin lymphoma
OM  Oral mucositis
OM0-1  Non-ulcerative mucositis
OM2-4  Ulcerative mucositis
OR  Odds ratios
OPC  Oropharyngeal carcinoma
OS  Overall survival
P4  Progesterone
PCR  Polymerase chain reaction
PR  Partial remission
PMN  Polymorphonuclear leukocyte
R-BEAM  Rituximab-BCNU, etoposide, cytosine arabinoside, melphalan
sIgA  Secretory immunoglobulin A
TBI  Total body irradiation
THR  Thrombocyte
TX  Transplantation
UWS  Unstimulated whole saliva
VGPR  Very good partial remission
WHO  World Health Organization
Z-BEAM  Zevalin-BCNU, etoposide, cytosine arabinoside, melphalan
There is a rise in incidence of malignant haematological diseases. Autologous and allogeneic haematopoietic stem 
cell transplantations (HSCT) are used with increasing frequency and efficiency as a  therapy1. High-dose intensive 
cytostatic treatment and in some cases total body irradiation (TBI) is employed as part of the transplantation 
process (myeloablative conditioning therapy). Oral mucositis (OM) is a common and severe complication, 
graded 0–4 according to the World Health Organization (WHO)2. Anticancer treatment-related mucosal damage 
affects not only the oral cavity but also the entire gastrointestinal tract (GI), therefore it is more appropriate to 
use the umbrella term of mucosal barrier injury (MBI). OM causing severe pain and extensive ulcers decreases 
quality of life and due to damage the protective mucosal barrier results in the dissemination of oral pathogens, 
leading to sepsis, which is often fatal in protracted neutropenia. Prolonged hospital stay increases the risk of 
nosocomial infections with high mortality and strain on the health care  system3. OM has several patient and 
anti-tumoural therapy related risk factors, such as nutritional deficiency, poor dental hygiene, previous exposure 
to prolonged immunosuppressive therapy and genetic variations affecting the pharmacodynamics of  cytostatics4. 
Excretion of chemotherapeutic drugs in the saliva is locally  cytotoxic2,5. Decreased salivary flow rate and altered 
saliva composition may enhance OM risk and  severity6. Despite strenuous efforts in research and therapy, OM 
treatment remains mainly supportive and palliative with basic oral care, pain control, feeding and prevention 
of  infections7. However, there are no predictive markers regarding the severity of OM in HSCT. Our goal was to 
assess and identify novel risk factors which could predict the severity of OM in haematological patients undergo-
ing autologous peripheral stem cell transplantation (APSCT).
Materials and methods
Retrospective study population and design.  In our study we conducted a restrospective analysis of 
192 patients over a period of 4 years who had required and undergone APSCT due to malignant haematological 
disorder in the Haematopoietic Transplantation Centre of the Clinical Centre of the University of Debrecen, 
Hungary. The study was approved by the Regional Istitutional Research Ethics Committee, Clinical Center, Uni-
versity of Debrecen (Ethical licence: DE RKEB/IKEB 4948-2018). Diagnoses were obtained from the institu-
tional electronic clinical database eMedSolution (T-Systems Inc. Budapest, Hungary) in accordance with the 
ethical approval. Written informed consents for inclusion, intraoral examination, blood and saliva sampling 
and research participation were obtained from all subjects and data were anonymised. No organs/tissues were 
procured from prisoners. All methods were carried out in accordance with relevant guidelines and regulations. 
The study was conducted in accordance with the Declaration of Helsinki. Eight patients were excluded due to 
non-compliance mainly related to disease severity.
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Two large patient groups were created, lymphoma (Hodgkin (HL) and non-Hodgkin’s lymphoma (NHL)) 
and multiple myeloma (MM). Regarding stage at disease onset all patients were early and advanced, respectively, 
while regarding stage prior to the transplantation we established two groups: complete remission (CR) and very 
good partial remission (VGPR) were merged as a single group, whereas partial remission (PR) represented a 
separate group. Response categories were determined in accordance with the International Myeloma Working 
group (IMWG) uniform response  criteria8. VGPR was defined as follows: serum and urine M-protein detectable 
by immunofixation but not on electrophoresis, or: 90% reduction in serum M-protein plus reduction in 24 h uri-
nary M-protein by > 90% or to < 100 mg/24 h. In partial remission more than 50% reduction of serum M-protein 
can be observed, and reduction in 24 h urinary M-protein by ≥ 90% or to < 200 mg/24 h, and 50% reduction in 
the size of any plasmacytomas present at baseline. In Hodgkin lymphoma we categorised the conditioning treat-
ments applied during the transplantation into four groups (1. BEAM, 2. R-BEAM, 3. R-BEAM-Adcetris, and 4. 
other). In NHL, in group 1 R-BEAM and in group 2 Z-BEAM conditioning regimen was used, whereas group 
3 represented cases with any other conditioning regimen. In MM conditioning was administration of 140 mg/
m2 melphalan in 12 patients and 200 mg/m2 in the rest of the patients. Treatment regimens according to the 
European Society for Blood and Marrow Transplantation (EBMT)  recommendation9,10 are summarized in Sup-
plementary Tables S1–S4. None of the patients received cryotherapy. After transplantation all patients received 
G-CSF with the following antimicrobial prohylaxis: (1) antibacterial prophylaxis: Leflokin (levofloxacin) 500 mg, 
(2) antifungal prophylaxis: Mycosyst (fluconazole) 100 mg and (3) antiviral prophylaxis: Herpesin (acyclovir) 
400 mg. OM was classified according to the World Health Organization (WHO) guidelines (Grade 0–4) and the 
most severe appearence defined the stage in the individual patient (0 none; 1 soreness ± erythema; 2 erythema, 
ulcers, and patient can swallow solid food; 3 ulcers with extensive erythema and patient cannot swallow solid 
food; 4 mucositis to the extent that alimentation is not possible)2.
For the statistical analysis there were two separate groups, (1) non-ulcerative (OM0-1) and (2) ulcerative 
(OM2-4)  mucositis11. Each participant had a check-up for focal dental infections and removal of infection foci 
prior to the transplantation. During transplantation, patients rinsed their mouths with 0.2% chlorhexidine-
digluconate (CHX) solution and performed atraumatic mechanical plaque control using a special dento-brush 
(DenTips MDS096502, Medline Industries. Inc., Mundelein, IL, USA) after every meal during cytopenia. The 
time required for neutrophil engraftment was calculated as number of days with < 0.5 Giga  (109) per Litre (G/L) 
absolute neutrophil count (ANC), and for thrombocyte engraftment as number of days with < 20 G/L throm-
bocyte (THR) count.
We analysed the relationship between oral mucositis developed during transplantation and the following 
continuous variables: age at time of transplantation, time elapsed between diagnosis and transplantation (DG-TX 
time/month), amount of stem cells administered  (106/body mass kg), stem cell viability (%), number of viable 
cells  (106/body mass kg) and mononuclear cells (MNC)  (108/body weight kg), engraftment time (ANC < 0.5 
G/L, THR < 20 G/L-days) and LDH (U/L). Of the categorical variables we analysed the relationship between 
oral mucositis and sex; stage of the disease at diagnosis (early versus advanced) and prior to transplantation (PR, 
VGPR, CR); the type of conditioning applied; outcome (dead or alive); infectious complications in the early 
post-transplantation stage (positive haemoculture); and correlation with disease subtype, where applicable. 
VGPR and CR, the stages immediately preceding transplantation, were conflated according to standard practice. 
Neutrophil engraftment is defined by peripheral absolute neutrophil count of ≥ 0.5 G/L, whereas thrombocyte 
engraftment by ≥ 20 G/L thombocytes, in three consecutive  days12. Thus in our study we characterised the time 
of engraftment with the ˂ 0.5 G/L ANC and ˂ 20 G/L THR days, respectively.
Based on their presumed hormonal status, the 85 female patients of the study were separated into pre-
menopausal (≤ 50 years) (n = 19) and postmenopausal (≥ 51 years) (n = 66) groups, respectively, according to 
published  criteria13. All premenopausal APSCT women were on hormone replacement therapy (HRT) (5–10 mg 
norethisterone-acetate on cycle days 3–27, prior to and after the day of the transplantation, as long as cytopenia 
persisted in order to reduce the risk of severe haemorrhagic complications).
Prospective study population and design.  Estradiol (E2) and progesterone (P4) levels in serum and 
saliva were determined in respective healthy controls (7 pre- and 7 postmenopausal women) and in 7 post-
menopausal patients with NHL undergoing APSCT, at four stages of transplantation (day − 7/− 3, 0, + 7, + 14). 
Sampling was performed in the Haematopoietic Transplantation Centre of the Clinical Centre of the University 
of Debrecen, Hungary in an 8-week period ending December 15th, 2018.
In regarding this measurement study design was aligned with STROBE recommendations and using sam-
ple size calculator Sampsize (epiGenesys, Sheffield, UK) this part of the study was a pilot. Average age was 
66.71 ± 5.85 years in the postmenopausal (A), 25.43 ± 1.62 years in the premenopausal (C) control group while 
54.42 ± 12.29 years in the transplantated group. Three patients were in complete morphological remission (CMR) 
and 4 in partial remission (PR) prior to transplantation.
Collection of serum samples.  Blood and saliva samplings were performed at the same timepoint on spec-
ified days of the peritransplantation period (on the day of hospital admission (day − 3/− 7), day of transplanta-
tion (day 0), days + 7 and + 14). Blood samples were collected using a clot activator containing serum tubes (BD, 
Franklin Lakes, NJ, USA), centrifuged at 1,200 × g for 30 min and the serum fractions were stored at − 70 °C until 
further processing.
Collection of unstimulated whole saliva (UWS) samples.  Sample collection was based on the proto-
cols described  previously14,15. In brief, following oral cavity rinse with 25 ml of physiological saline solution (B. 
Braun Melsungen AG, Melsungen, Germany) for 30 s, saliva was collected for 5 min in 15 ml disposable, pre-
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disinfected tubes (Sigma-Aldrich, St. Louis, MO, USA). Participants adapted to the condition for 5 min. Taking 
into account the diurnal variation of saliva constituents, samplings were done every morning at the same time, 
1 h after eating, drinking or toothbrushing. Patients in the Haematopoietic Stem Cell Transplantation Centre’s 
steril rooms used a steril disposable oral swab (DenTips MDS096502, Medline Industries.Inc., Mundelein, IL, 
USA) impregnated with physiological saline solution to maintain oral hygiene during the period of cytopenia. 
Protease Inhibitor (Sigma-Aldrich, St. Louis, MO, USA) was added to the collected saliva samples and after ali-
quoting into 1.5 ml Eppendorf tubes, samples were stored at − 70 °C until processing.
Detection of salivary and blood sample E2 and P4 levels.  Saliva and serum samples stored at − 70 °C 
were thawed at room temperature and centrifuged at 4 °C for 10 min at 3,000 rpm. Serum (500 µl) and diluted 
saliva supernatant (150 µl in 450 µl Hanks’ Balanced Salt solution (Sigma-Aldrich, St. Louis, MO, USA) were 
filtered through 70 µm EASYstrainer cell sieve (Greiner Bio-One, Frickenhausen, Germany). Hormone levels 
were determined using electrochemiluminescence immunoassay (ECLIA) (Roche, Basel, Switzerland).
Statistical analysis.  Statistical analysis was performed using IBM SPSS22 software (IBM, Armonk, NY, 
USA). Kolmogorov–Smirnov test was used to investigate the normal distribution of data. In case of normal 
distribution, we compared the two groups using independent sample t-test in the continuous variables, whereas 
in non-normal distribution we applied Mann–Whitney and Wilcoxon tests. For distribution of categorical vari-
ables Chi-square test and Fischer exact test were used. Overall survival (OS) was calculated from the time of 
diagnosis to the last follow-up visit or death. Survival data were analyzed using the Kaplan–Meier method with 
log-rank test. Odds Ratios (OR) were obtained using binary logistic regression models. p < 0.05 was considered 
significant.
Results
Retrospective analysis of primary outcome of patients who underwent APSCT.  The reason for 
HSCT was lymphoma (NHL-HL) in 85 patients and MM in 107 patients. Mean age of the 107 male patients was 
54.87 ± 11.64 years (17–72 years) and of the 85 female patients was 56.13 ± 11.38 years (24–71 years). There was 
no significant difference between NHL-HL and MM groups regarding age and sex. The OM grade varied from 
grade 1 (n = 4), 2 (n = 9), 3 (n = 7) to 4 (n = 4) in HL; from grade 1 (n = 35); 2 (n = 37), 3 (n = 20) to 4 (n = 8) in MM; 
from grade 1 (n = 14), 2 (n = 19), 3(n = 18) to 4 (n = 7) in NHL. Considering all patients irrespective of underlying 
disease (n = 192), 10 did not have OM (grade 0), 53 developed grade 1, 65 had grade 2, 45 had grade 3, and 19 
had grade 4 OM. In the combined lymphoma group (NHL-HL) 18 patients showed grade 1, 28 grade 2, 25 grade 
3, and 11 grade 4 OM (Supplementary Fig. S1).
In the all patient group continuous variables DG-TX time (pre-treatment time) (p = 0.022), neutrophil engraft-
ment (p < 0.001), thrombocyte engraftment (p < 0.001) and categorical variable female sex (p = 0.033) showed a 
significant correlation with more severe OM. There was a positive non-significant association between OM2-4 
and higher LDH value (p = 0.07) and haemoculture positivity (p = 0.092). In the lymphoma group the continuous 
variables neutrophil engraftment (p = 0.005) and thrombocyte engraftment (p = 0.005) and the categorical vari-
able female sex (p = 0.008) showed a significant correlation with OM2-4. In the myeloma group, the neutrophil 
engraftment (p = 0.011) and immunoglobulin G (IgG) (p = 0.049) subgroup of MM showed a significant correla-
tion with OM2-4. The other examined variables showed no correlation with the development of oral mucositis 
occurring during APSCT (Table 1).
Univariable analysis revealed in the all patient group in terms of OM2-4 the following prognostic factors: 
neutrophil engraftment (OR 1.461, 95% CI 1.225–1.744, p < 0.001), thrombocyte engraftment (OR 1.178, 95% CI 
1.078–1.288, p < 0.001), female sex (OR 1.969, 95% CI 1.052–3.687, p = 0.034) and lymphoma group (OR 1.969, 
95% CI 1.052–3.678, p = 0.034). Increased LDH values (OR 1.004, 95% CI 1–1.009, p = 0.067) and cases with 
positive haemoculture (OR 1.901, 95% CI 0.894–1.041, p = 0.095) may represent higher risks in the develop-
ment of more severe OM. In the lymphoma subgroup, in addition to neutrophil engraftment (OR 1.584, 95% CI 
1.134–2.214, p = 0.007), thrombocyte engraftment (OR 1.279, 95% CI 1.043–1.57, p = 0.018) and female sex (OR 
5.294, 95% CI 1.418–19.762, p = 0.013), absence of B symptoms (OR 7.000, 95% CI 1.085–45.16, p = 0.041) turned 
out to be prognostic factors of OM2-4. Hodgkin and non-Hodgkin’s lymphoma subgroups were combined due 
to the small number of cases in the HL group. Absence of B symptoms by itself did not appear as a prognostic 
factor among patients with NHL. In the myeloma group, neutrophil engraftment (OR 1.39, 95% CI 1.09–1.773, 
p = 0.008) and thrombocyte engraftment (OR 1.128, 95% CI 1.009–1.262, p = 0.034) were prognostic factors while 
the IgG subgroup (OR 2.766, 95% CI 0.984–7.773, p = 0.054) suggests a higher risk for the development of OM.
Multivariable analysis revealed that in the all patient group and in the lymphoma group neutrophil engraft-
ment (OR 1.492, 95% CI 1.228–1.813, p < 0.001; OR 1.476, 95% CI 1.061–2.052, p = 0.021) and female sex (OR 
2.301, 95% CI 1.124–4.714, p = 0.023; OR 4.190, 95% CI 1.081–16.240; p = 0.038) could be considered independ-
ent predictive factors (Classification ratio: 67.7%, Nagelkerke coefficient: 0.172); (Classification ratio: 78.8%, 
Nagelkerke coefficient: 0.236) in the development of OM2-4. In the myeloma group neutrophil engraftment 
(OR 1.39, 95% CI 1.09–1.773, p = 0.008) (Classification ratio: 62.6%, Nagelkerke coefficient: 0.105) appeared as 
an independent prognostic factor (Table 2).
Time to neutrophil engraftment (7.774 ± 2.10 days) was significantly (p < 0.001) longer in the lymphoma 
group than in the MM (5.80 ± 2.07 days). At the same time, neutrophil engraftment was the strongest predictive 
factor in the NHL group (OR 1.598, 95% CI 1.101–2.321, p = 0.014); (thrombocyte engraftment: OR 1.239, 95% 
CI 1.004–1.529, p = 0.046; female sex: OR 5.320, 95% CI 1.077–26.276, p = 0.040) (Fig. 1).
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Secondary outcomes of  retrospective  analysis  of women who underwent APSCT.  As next, 
since female sex has been shown to have a major role in the development of OM2-4, we conducted further 
analysis.
The 85 female patients were classified into two groups based on their hormonal  status13. Patients ≤ 50 years 
were grouped as premenopausal and those ≥ 51 years as postmenopausal, as we mentioned earlier. Based on 
this classificiation 19 women were premenopausal and 66 postmenopausal. Of the 19, 15 (78.95%), and of the 
Table 1.  Association of variables with oral mucositis in the different patient groups. p < 0.05 was considered 
significant. p values with bold are significant, while with italic, are non-significant, but close to it. Statistical 
analysis: independent samples t-test, Mann–Whitney test, Chi-square test and Fisher’s exact test were used. 
ANC absolute neutrophil count, Dg diagnosis, IgA immunoglobulin A, IgG immunoglobulin G, LDH lactate-
dehydrogenase, n numero, OM oral mucositis, THR thrombocyte count, Tx transplantation.
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time of Tx 
(years)









6.43 ± 1.99 6.561 ± 2.066 0.617 6.58 ± 2.15 6.49 ± 2.30 0.829 6.263 ± 1.819 6.599 ± 1.963 0.331









4.29 ± 3.54 3.964 ± 2.592 0.826 4.86 ± 4.30 4.40 ± 2.43 0.828 3.671 ± 2.375 3.759 ± 2.671 0.978
ANC ˂  0.5 
G/L (days) 7.17 ± 2.38 5.62 ± 1.679 < 0.001 8.11 ± 2.16 6.62 ± 1.46 0.005 6.25 ± 2.236 5.12 ± 1.565 0.011
THR ˂  20 G/L
(days) 8.33 ± 5.01 5.07 ± 3.104 < 0.001 10.16 ± 4.70 7.62 ± 2.76 0.005 6.52 ± 4.667 4.74 ± 2.829 0.132
LDH (U/L) 248.45 ± 107.77 218.607 ± 68.58 0.070 273.37 ± 130.71 230.05 ± 58.36 0.305 221.709 ± 67.44 212.25 ± 73.654 0.279
n (%) p n (%) p n (%) p
Male 65 (50%) 42 (67%) 0.033 34 (53%) 18 (86%)3 (14%) 0.008 31 (48%) 24 (57%) 0.340
Female 64 (50%) 21 (33%) 30 (47%) 34 (52%) 18 (43%)
Stage at the time of the diagnosis
I–II 19 (46%) 15 (56%) 4 (20%) 15 (71%) 14 (74%)
0.873
II–III 22 (54%) 12 (44%) 0.457 16 (80%) 6 (29%) 5 (26%)
Pretransplantational stage
I–II 70 (59%) 35 (62%) 0.689 38 (64%) 32 (54%) 26 (68%)
0.164
II–III 48 (41%) 21 (38%) 21 (36%) 27 (46%) 12 (32%)
Conditional therapy
1 31 (51%) 10 (48%)
2 10 (17%) 5 (24%)
3 15 (25%) 6 (28%)
4 4 (7%) 0
Last status
1 35 (27%) 10 (16%) 0.084 18 (28%) 17 (26%) 6 (14%)
0.144
0 94 (73%) 53 (84%) 46 (72%) 48 (74%) 36 (86%)
Infection
1 37 (29%) 11 (17%) 0.092 23 (36%) 14 (22%) 4 (10%)
0.105
0 92 (71%) 52 (83%) 41 (64%) 51 (78%) 38 (90%)
IgA/IgG
1 – – – – 9 (17%) 11 (37%)
0.049
2 – – – 43 (83) 19 (63%)
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Table 2.  Risk factors of oral mucositis. p < 0.05 was considered significant. p values with bold are significant, 
while with italic, are non-significant, but close to it. Statistical analysis: binary logistic regression was used. ANC 
absolute neutrophil count, Dg diagnosis, HL Hodgkin lymphoma, IgA immunoglobulin A, IgG immunoglobulin 
G, L lymphoma, LDH lactate-dehydrogenase, MM Multiple myeloma, MNC mononuclear cells, n numero, NHL 
Non-Hodgkin’s lymphoma, OM oral mucositis, THR thrombocyte count, Tx transplantation.
Total patients Lymphoma Myeloma multiplex
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Univariable analysis
Age at the time of Tx (years) 0.988 (0.964–1.015) 0.371 0.988 (0.952–1.025) 0.526 1.024 (0.970–1.082) 0.384
Dg-Tx time interval (months) 1.004 (0.991–1.016) 0.542 0.999 (0.985–1.013) 0.897 0.999 (0.970–1.029) 0.950
Amount of stem cells
(106/body mass kg) 0.967 (0.830–1.127) 0.668 1.021 (0.81–1.285) 0.863 0.908 (0.731–1.127) 0.382
Viability (%) 1.022 (0.959–1.090) 0.503 1.016 (0.925–1.116) 0.744 1.062 (0.963–1.172) 0.226
Amount of viable cells
(106/body mass kg) 0.965 (0.813–1.146) 0.688 1.025 (0.787–1.335) 0.853 0.909 (0.715–1.157) 0.439
MNC
(108/body mass kg) 1.033 (0.930–1.147) 0.547 1.034 (0.89–1.2) 0.664 0.989 (0.833–1.166) 0.868
ANC < 0.5 G/L (days) 1.461 (1.225–1.744) < 0.001 1.584 (1.134–2.214) 0.007 1.39 (1.09–1.773) 0.008
THR < 20 G/L (days) 1.178 (1.078–1.288) < 0.001 1.279 (1.043–1.57) 0.018 1.128 (1.009–1.262) 0.034
LDH (U/L) 1.004 (1–1.009) 0.067 1.005 (0.998–1.012) 0.168 1.002 (0.996–1.008) 0.526
Female versus male 1.969 (1.052–3.687) 0.034 5.294 (1.418–19.762) 0.013 1.462 (0.67–3.194) 0.340
Advanced stage at the time of the 
diagnosis 1.447 (0.545–3.842) 0.458 0.571 (0.054–6.079) 0.643 1.120 (0.278–4.508) 0.873
Advanced stage before transplantation 1.143 (0.594–2.198) 0.689 0.553 (0.19–1.606) 0.276 1.828 (0.778–4.297) 0.166
Infection 1.901 (0.894–1.041) 0.095 1.122 (0.396–3.178) 0.828 2.608 (0.795–8.554) 0.114
HL-NHL 1.455 (0.468–4.524) 0.518 1.455 (0.468–4.524) 0.518 – –
MM-NHL 0.563 (0.282–1.124) 0.103 – – – –
L-MM 1.969 (1.052–3.687) 0.034 – – – –
Stage of missing of B symptoms – – 7.000 (1.085–45.16) 0.041
IgA versus IgG – – – – 2.766 (0.984–7.773) 0.054
Kappa versus lambda – – – – 0.644 (0.291–1.425) 0.277
Dosis of melphalan (≥ 200 mg/m2) – – – – 1.046 (0.301–3.629) 0.944
MM pretreatment – – – – 1.559 (0.464–5.231) 0.472
Multivariable analysis
ANC ˂  0.5 G/L (days) 1.492 (1.228–1.813) < 0.001 1.476 (1.061–2.052) 0.021 1.39 (1.09–1.773) 0.008
Gender 2.301 (1.124–4.714) 0.023 4.190 (1.081–16.240) 0.038
Figure 1.  Risk factors and independent predictive factors of oral mucositis. ANC absolute neutrophil count, 
HL Hodgkin lymphoma, IgG immunoglobulin G, LDH lactate-dehydrogenase, NHL Non-Hodgkin’s lymphoma, 
THR thrombocyte count. Flowchart summary of statistical tests’ results. Colour codes/Letter markings: 
Red: independent prognostic factors revealed by multivariable analysis Black: prognostic factors revealed by 
multivariable analysis Green: higher risk in terms of ulcerative mucositis by univariable analysis.
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66, 49 (74.24%) patients developed ulcerative mucositis (OM2-4). There was no significant difference between 
the two groups (p = 0.771).
We did our calculations for the total patient group and the individual patient group, respectively, and got 
similar results. In the lymphoma subgroup 16 (88.89%) out of 18 premenopausal women, while 14 (93.33%) 
out of 15 postmenopausal women developed severe OM. The difference was not significant here, either (p = 1). 
In the myeloma group, 33 out of 49 postmenopausal female patients developed ulcerative OM while the cor-
responding ratio in the premenopausal group was 1 out of 3 (33.33%). No significant difference was found here, 
either (p = 0.114).
However, ulcerative mucositis was significantly (p = 0.009) more frequent in the lymphoma group than in 
the MM group (30 of the 33 patients with lymphoma-90.9%, while 34 out of the 53 patients with MM-65.38%, 
p = 0.009).
Overall survival with and without ulcerative mucositis.  Correlation was assessed between average 
post-transplantational survival time and ulcerative mucositis. OS was 5.17  months shorter in the combined 
patient group (HL, NHL, MM) if ulcerative mucositis developed (OM2-4: 35.34 months (31.83–38.85); OM0-1: 
40.51 months (26.42–44.61) (p = 0.101) (Fig. 2).
Determination of serum and salivary E2 and P4 levels.  A physiological decrease was observed in 
serum E2 level in the postmenopausal control group (A) compared to the premenopausal (C) (p = 0.004), while 
there was no significant difference in salivary E2 level (p = 0.069). Both in serum and saliva, P4 levels were signif-
icantly decreased in the postmenopausal controls compared to the premenopausal group (p = 0.017, p = 0.004).
Serum P4 was more elevated in the transplantated patients compared to the postmenopausal controls at all 
four stages of transplantation, at day + 7 significantly (p = 0.026). Salivary P4 was higher, although not significantly 
at days + 7 and + 14 compared to the two other stages of APSCT and to controls (≥ 51), respectively. Although 
decrease in salivary P4 level was significant in the postmenopausal controls compared to the premenopausals, 
a tendency for increase was observed in postmenopausal APSCT patients at day + 7 and day + 14 compared not 
only to the postmenopausal controls, but also to the premenopausals (Fig. 3).
Serum E2 decreased significantly (p = 0.004) in the patient group compared to the premenopausal controls, 
while there was no significant difference between E2 serum and salivary hormone levels of postmenopausal 
controls and patients with NHL undergoing APSCT in the postmenopause. In summary, we didn’t find any 
significant changes of E2 in relation to NHL and/or due to the APSCT in the patient group.
Unstimulated whole saliva (UWS) in controls and in patients during APSCT.  There was no sig-
nificant difference (p = 0.628) in UWS flow rate between the pre- and postmenopausal control groups. During 
APSCT, significant decrease was observed at day 0, day + 7 and day + 14 in UWS flow rate between the pre- and 
postmenopausal control groups (p = 0.004, p = 0.004, p = 0.004); (p = 0.048, p = 0.030, p = 0.018), and between the 
day of admission of APSCT (day − 3/− 7) (p = 0.043, p = 0.043, p = 0.043), respectively (Fig. 4). There was a signifi-
cant positive correlation (p = 0.008, r = 0.928) between serum E2 level and UWS flow rate in the premenopausal 
group.
Discussion
OM is associated with increased mortality in haematological malignancies. Numerous studies have attempted 
to prevent it or reduce its severity, with limited  success7. There is a new wave in OM studies with focus on risk 
factors implicated in other diseases of the oral cavity including cancer. Our results indicate that neutrophil 
engraftment is an independent predictive factor of OM both in lymphoma and MM whereas female sex predis-
poses to ulcerative OM in lymphoma only.
Figure 2.  Kaplan–Meier overall survival curves of patient groups. Analysis of overall survival (OS) with (OM2-
4) and without (OM0-1) ulcerative mucositis.
8
Vol:.(1234567890)







































































































































Figure 3.  Saliva and serum levels of estrogen (E2) and progesterone (P4) in the pre- and postmenopausal control groups and 
during APSCT (autologous peripheral stem cell transplantation). (A) Serum and salivary E2 levels in the control groups. Serum E2 
decreased significantly (p = 0.004) in the postmenopausal group compared to the premenopausal group. There was no significant 
difference (p = 0.069) in salivary E2 levels. (B) Serum and salivary P4 levels in the control groups. Both in serum and saliva P4 levels 
were significantly decreased in the postmenopausals compared to the premenopausals (p = 0.017, p = 0.004). (C) Serum P4 levels in 
the postmenopausal control group compared to the transplantated patients. Significant difference was observed at day + 7 (0.026). 
(D) Salivary P4 levels in the postmenopausal control group and in the transplantated group. A tendency for increase was observed 
at days + 7 and + 14. (E) Salivary P4 levels in the premenopausal control group and in the transplantated patients. Physiological 
significant decreased was observed in remission (day − 3/ − 7) and day 0, and a tendency for elevation at days + 7 and + 14 compared to 
the premenopausal controls. On the X axis C is for premenopausal control group and A is for postmenopausal control group. Values 
are expressed as sample means; error bars represent the estimates of standard deviations calculated from three parallel measurements 
(*p < 0.05, **p < 0.01, ***p < 0.001). Statistical analysis: Kolmogorov–Smirnov test, Mann–Whitney test, Wilcoxon test.
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Serum LDH levels.  Pre-transplantation serum LDH levels are a good reflection of the remaining tumour 
mass, thus its prognostic role is important. Huang et  al. examined the prognostic value of pre-radiotherapy 
serum LDH levels in patients with non-metastatic oropharyngeal carcinoma (OPC)16. Their results showed that 
increased LDH levels in HPV+ OPC patients were an independent prognostic factor in terms of survival. The 
results of our own study suggest that with marginally increased pre-transplantational serum LDH levels a higher 
prevalence of ulcerative oral mucositis can be predicted, which supports its negative prognostic role.
Neutrophil engraftment and oral mucositis.  Neutrophils in the first lines of defense play a crucial 
role in protection againts infections and promote wound  healing17. Platelets contribute to tissue remodelling 
after injury and  inflammation18. Timely insertion and proliferation of stem cells in neutrophil and thrombocyte 
engraftments are essential in reducing risk and severity of OM. Earlier studies have reported at length on the 
relationship between neutrophil engraftment and OM, and the positive correlation has also been confirmed 
between the duration of mucositis and neutrophil  engraftment19. Reduced as opposed to standard dose MTX in 
allogeneic HSCT patients resulted in shorter neutrophil engraftment time and faster recovery from  mucositis19. 
The anti-inflammatory, antioxidant and wound-healing promoting effects of erythropoietin containing mouth-
wash in patients who underwent APSCT, reducing severity and incidence of OM without significant effect on 
blood neutrophil and thrombocyte  engraftment12, further supports the role of local factors in the aetiology and 
therapy of OM. Several studies have unanimously concluded that oral engraftment is an earlier sign of adherence 
and recovery of stem cells than blood engraftment. Furthermore, it is a more sensitive indicator of oral mucositis 
and reflects the status of local  immunity20–22.
Female sex.  The predictive role of the female sex regarding OM in APSCT has been confirmed by earlier 
 studies23,24, however, no in-depth analysis like our study has been reported. The dose of chemotherapy applied 
over a larger body surface area (BSA) per body mass in women may explain the sex  difference25. Furthermore, 
women have increased risk of cytotoxicity and oral mucositis possibly partially due to hormone-related post-
translational  modifications26. We confirmed that APSCT-related OM was more frequent and severe in women 
than in men. Severe ulcerative OM (OM2-4) was more frequent in lymphoma than in myeloma, pontentially 
due to the longer pre-treatment time. There was no significant difference in incidence of ulcerative OM between 
pre- and postmenopauls. To explain this, we conducted hormonal analysis in the prospective part of our study. 
In the postmenopause E2 levels were physiologically decreased (Fig. 3A). In premenopausal patients, hormone 
levels were affected by progestin and norethisterone-acetate administered before and during transplantation to 
reduce the risk of haemorrhagic complications. However, we observed significantly increased serum progester-
one levels at day + 7 of APSCT (which is the deepest point of cytopenia and the most severe grade of OM) also 
in postmenopausal patients with lymphoma (Fig. 3C), who also had increased incidence and severity of OM in 
our retrospective analysis. Therefore, we assume that the hormonal changes identified in our study (increased 
progesterone in postmenopausal patients in particular) do exert a strong effect on OM development. It is gener-
ally known that sex hormones have direct and indirect effects on the physiology of the oral cavity. In future stud-





































Figure 4.  Salivary flow rate of unstimulated whole saliva (UWS) in controls and in patients during autologous 
peripheral stem cell transplantation (APSCT). On the X axis C is for premenopausal control group and A is 
for postmenopausal control group. Values are expressed as sample means; error bars represent the estimates of 
standard deviations calculated from three parallel measurements (*p < 0.05, **p < 0.01, ***p < 0.001). Statistical 
analysis: Kolmogorov–Smirnov test, Mann–Whitney test and Wilcoxon test. 
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the saliva and function of the immune system could be correlated with tissue-specific localization, quantity and 
functional status of sex hormone receptors.
Oral epithelium.  The adverse effect of decreased serum estrogen on the mucosa is well known: the oral 
epithelium becomes thin and atrophic, accompanied by a deterioration of mucosal integrity and  immunity27, 
whereas estrogen supplementation and HRT improves mucosal  integrity28–30. The oral mucosa also responds 
to  progesterone31, high levels being detrimental, especially in immuno-compromised  patients32–34. There were 
elevated serum and salivary progesterone levels in our patients during APSCT (Fig. 3C,D,E).
Periodontium and oral microbiome.  The increased sensitivity of periodontal tissues to sex hormones 
has been widely investigated. Estrogen increases epithelial keratinization, stimulates proliferation of fibroblasts 
and epithelial basal cells in the  gingiva27,35. In postmenopausal women the prevalence of periodontitis is sig-
nificantly higher compared with  premenopausals36. Periodontal pathogens such as Porphyromonas gingivalis, 
Tannerella forsythia, Prevotella intermedia play a role in the development and progression of periodontitis, while 
HRT decreases the amount of this pathogen  flora37,38. In our patients with APSCT-related cytopenia the cycle 
was suspended with norethisterone-acetate. This progestin decreases keratinization, favours colonisation of 
Gram-negative bacteria (e.g. Bacteroides, Prevotella sp.). Progesterone also enhances inflammatory response to 
local irritative factors thereby increasing the risk and severity of  OM35. These findings support the notion that 
the predictive role of female sex in the development of OM during APSCT is a consequence of the shifted hor-
monal balance.
During HSCT, patients with chronic gingivitis or periodontitis have higher incidence of bacteriaemia and 
ulcerative  mucositis39. In the preengraftment stage there is often anaerob blood stream infection (ABI) with 
Fusobacterium and Porphyromonas species of oral and upper GI tract origin, whereas during postengraftment 
Bacteroides and Clostridium species of lower GI tract origin  colonize40. Changes in microbial diversity occure 
rapidly in patients with ulcerative oral mucositis during  APSCT41. However, we did not find significant correla-
tion between evidence of infection by haemoculture and ulcerative oral mucositis (OM2-4) in our retrospective 
study. Futher research is recommended with wider range of methods, such as swab culture and polymerase 
chain reaction (PCR).
In conclusion, hormonal changes (particularly decreased E2 and increased P4 levels) have a negative effect 
on the periodontium and favour the proliferation of periodonthopathogens, which play an increased role in the 
development of bacteriaemia and ulcerative OM during HSCT.
Salivary glands and saliva.  Saliva has a fundamental role in the homeostasis of the oral cavity, lubrication 
of the mucosa, and protection against microorganisms and oxidative stress. Changes in its organic and anorganic 
components act as a sensitive mirror of the body’s defence mechanisms. Its diagnostic importance is outstanding 
and comparable with the serum. Steroid hormone levels in the saliva usually correlate with the active hormone 
levels in the  serum42,43. Our salivary P4 results correlated well with serum P4 levels both in healthy controls and 
in the transplantated patients (Fig. 3), whereas it did not reach the level of significance regarding salivary E2. 
Salivary secretion and changes in its components are under significant sex hormone regulation and estrogen 
and progesterone receptors are present in the salivary  glands31,44. Most studies report decreased salivary flow 
rate in postmenopause noting the positive effect of  HRT45,46, while others enhance the decrease of stimulated 
whole saliva  only47,48. We found no significant difference in UWS flow rate between the pre-and postmenopausal 
controls, and a positive correlation between serum E2 level and UWS flow rate in the premenopausals (Fig. 4). 
Several studies have demonstrated decreased salivary flow rate during APSCT under the influence of condition-
ing  treatment6, in concert with our results (Fig. 4).
There is impairment of salivary antimicrobial defence and mucosal integrity during  APSCT6,49. Thus, we can 
conclude that postmenopausal hormonal changes increase the risk of OM that occurs during APSCT.
Oral immunity.  Although the interactions involved are not yet completely understood, the interrelation-
ship between production of sex hormones and the functioning of the immune system has been confirmed in 
many  studies35. This is also supported by increased incidence of autoimmune diseases among  women35. Estro-
gen has a stimulating effect on the immune system, as opposed to progesterone and  androgens50. E2 regulates 
glycosylation of IgG and its role in immunological  processes51. Also, salivary secretory immunoglobulin A 
(sIgA) levels change parallel to serum E2  levels52 and altered N-glycosylation of salivary sIgA and serum IgA is 
a possible biomarker in oral  mucositis15. Importantly, high-dose progesterone attenuates the antibacterial activ-
ity of  neutrophils53, whereas decreased estrogen aggravates dento-alveolar  infections54 and impairs leukocyte 
 chemotaxis35. These observations further underline the importance of sex hormones in OM and their relevance 
to APSCT. Their role in PMN chemotaxis may be crucial in ulcerative OM development and support our finding 
that neutrophil engraftment is an independent prognostic factor of OM.
conclusion
Hormonal changes in women play a fundamental role in the aetiopathogenesis of OM during APSCT. These 
changes may exert their complex effect directly or indirectly on components of saliva and on oral epithelium, 
microbiome and immunity. Decreased estrogen levels adversely affect several aspects of oral homeostasis, and 
elevated progesterone levels both in serum and saliva may play a role in the weakening of the mucosal barriers 
not only in the pre- but also in postmenopause in particular during APSCT. Monitoring serum progesterone 
levels in women undergoing APSCT may be a suitable tool in the assesment of mucosal immunity, function and 
risk of severe OM.
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